CONMED Corp (CNMD) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-02

Key Insights

The CEO received a $1M equity award in the form of restricted stock units (RSUs) that will vest over 3 years with a 2-year post-vest holding period.
The CEO's increased stake in the company through this RSU grant aligns his interests with those of shareholders.
The timing of the award, just before the end of the fiscal year, suggests the company may be rewarding the CEO for strong performance.

Want the newest filings?

This analysis covers the filing from 2026-04-02. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-04

Brent Lalomia, the Executive VP RA, QA of CONMED Corporation, acquired 9,554 restricted stock units (RSUs) and 11,322 stock options on March 2, 2026, indicating the company's commitment to incentivizing its key executive team.
The RSUs and options granted to Lalomia have a 10-year expiration period, suggesting a long-term alignment between the executive's interests and those of CONMED's shareholders.
The granted RSUs and options are subject to vesting schedules, which could provide an incentive for Lalomia to focus on CONMED's long-term performance and growth.

Filed: 2026-03-04

Matthew Schabacker, VP GM of Advanced Surgical at CONMED Corporation, acquired 9,827 restricted stock units (RSUs) and 11,646 stock options on March 2, 2026, indicating his confidence in the company's future performance.
The RSUs and stock options granted to Schabacker are subject to vesting schedules, aligning his interests with long-term shareholder value creation.
Insider transactions, such as this acquisition of equity-based awards, can provide insights into management's views on the company's prospects and growth potential.

Filed: 2026-03-04

John D. Ferrell, the Executive Vice President of HR at CONMED Corporation, has been granted 9,282 restricted stock units (RSUs) and 10,999 stock options, which will vest over a multi-year period, indicating the company's commitment to incentivizing and retaining its key executive talent.
The granted RSUs and stock options have an expiration date of March 2, 2036, providing Ferrell with long-term alignment with CONMED's performance and shareholder value creation.
This insider transaction suggests CONMED's leadership believes in the company's future prospects and is willing to invest their own compensation in the form of equity awards.

Filed: 2026-03-04

Johonna Marie Pelletier, the Treasurer and VP of Tax at CONMED Corp, has been granted 5,896 restricted stock units (RSUs) that will vest over a three-year period.
The RSU grant is part of the company's 2025 Long-Term Incentive Plan, which aligns the executive's interests with those of the shareholders.
This insider grant of equity-based compensation suggests Pelletier's commitment to CONMED's long-term growth and performance.

Filed: 2026-03-04

Peter K. Shagory, the EVP of Strategy and Corporate Development at CONMED Corp, acquired 9,282 restricted stock units (RSUs) and 10,999 stock options on March 2, 2026, indicating his commitment to the company's long-term success.
The RSUs and stock options are subject to vesting schedules, aligning Shagory's interests with those of CONMED's shareholders.
Insider transactions like this can provide insights into management's confidence in the company's future prospects and their alignment with shareholder value creation.

Filed: 2026-03-04

Hollie K. Foust, the General Counsel and Corporate Secretary of CONMED Corporation, acquired 10,919 restricted stock units (RSUs) and 12,940 stock options on March 2, 2026, indicating insider confidence in the company's future performance.
The RSUs and stock options have vesting periods of 3 years and 4 years respectively, suggesting a long-term commitment from the reporting person.
The transaction increases Foust's beneficial ownership of CONMED securities, potentially aligning her interests with those of shareholders.

Filed: 2026-03-04

The reporting person, Andrew James Moller, has been granted 5,896 restricted stock units (RSUs) of CONMED Corporation, which will vest over a 3-year period.
The RSUs were granted on March 2, 2026 and will expire on March 2, 2036, indicating a long-term incentive for the reporting person.
The reporting person currently holds 5,896 RSUs, which represents their direct ownership in CONMED Corporation's common stock.

Filed: 2026-03-04

The CEO of CONMED Corporation, Pat Beyer, has been granted 28,800 restricted stock units (RSUs) and 68,258 stock options, indicating confidence in the company's long-term growth prospects.
The RSUs and stock options have a 10-year vesting period, aligning the CEO's incentives with long-term shareholder value creation.
The timing of this equity award, granted in March 2026, suggests the company may be preparing for a new strategic initiative or growth phase.

Filed: 2026-02-26

Mark Kaye, a director at CONMED Corp, exercised 152 restricted stock units (RSUs) on 02/24/2026, indicating his continued ownership and commitment to the company.
The vesting of the RSUs aligns Kaye's interests with shareholders, as the RSUs represent a contingent right to receive CONMED common stock.
This transaction represents a routine insider event and does not signal any significant changes to Kaye's overall ownership or the company's outlook.

Other reports for CONMED Corp

Quarterly Report Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.